Eureka nets $60M to take T-cell therapy into the clinic – FierceBiotech
FierceBiotech |
Eureka nets $60M to take T–cell therapy into the clinic
FierceBiotech The FDA approved the first two CAR-T treatments for blood cancers—Novartis' Kymriah and Kite and Gilead's Yescarta—in 2017, but the agency still flags cytokine release syndrome and neurotoxicity as “significant safety issues” tied to this type of … Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor … |
